Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 23, Issue 2, Pages e48-e50
Case Report

Daptomycin-Nonsusceptible, Vancomycin-Intermediate, Methicillin-Resistant Staphylococcus aureus Endocarditis

Ryan Yu,1 Suzanne E Dale,2,3 Deborah Yamamura,2,3 Vida Stankus,4 and Christine Lee2,3

1Michael G DeGroote School of Medicine, McMaster University, Canada
2Hamilton Regional Laboratory Medicine Programme, St Joseph’s Healthcare, Canada
3Department of Pathology and Molecular Medicine, McMaster University, Canada
4Department of Pharmacy, Hamilton Regional Laboratory Medicine Programme, St Joseph’s Healthcare, Hamilton, Ontario, Canada

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.